Umirolimus

Drug Profile

Umirolimus

Alternative Names: A9; AXXESS; Ba9; BioFreedom; Biolimus A9 (BA9); Biolimus A9-eluting stent; Biolimus-A9; BioMatrix; BioMatrix Flex; BioMatrix NeoFlex; BMX-J; Custom NX; Nobori; TRM-986

Latest Information Update: 15 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biosensors International Pte Ltd
  • Developer Biosensors International Group; Terumo
  • Class Macrolides
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Coronary artery restenosis
  • Phase III Coronary artery disease

Most Recent Events

  • 11 Sep 2017 Phase-III development for Coronary artery disease is ongoing in Canada (Intracoronary) (NCT02843633)
  • 21 Apr 2017 Biosensors Europe plans a clinical trial for Coronary artery disease in Switzerland and United Kingdom (NCT03118895)
  • 09 Feb 2015 Biosensors International Group completes enrolment in the phase III Leaders Free Japan trial in Coronary artery disease in Japan (NCT02348021)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top